Hosted on MSN4h
Canaccord Genuity Downgrades Intra-Cellular Therapies (ITCI)
Fintel reports that on January 31, 2025, Canaccord Genuity downgraded their outlook for Intra-Cellular Therapies ...
Canaccord cuts Intra-Cellular stock rating, raises target to $132
Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...
InvestmentNews1d
Advisors explain how to keep intra-family loans from fracturing relationships
A new study confirms a fact most financial advisors are already acutely aware of: Intra-family lending can cause problems.
BioSpace8d
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
Seeking Alpha1d
ITCI Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in ...